🧠 Food for thought

Implications, context, and why it matters.

Patch pumps represent fastest-growing segment in expanding insulin delivery market

• ViCentra’s timing aligns with strong market tailwinds, as patch pumps represent the fastest-growing segment of the insulin delivery market1.
• The broader insulin pump market is projected to grow from $4.31 billion in 2024 to $7.27 billion by 2030, with a compound annual growth rate of 9.10%1.
• This growth is driven by rising diabetes prevalence, with projections showing cases will increase from 366 million in 2011 to 552 million by 20302.
• ViCentra’s €72.4 million raise positions them to capture market share during this expansion phase, particularly as they prepare for U.S. market entry where adoption of advanced insulin delivery systems continues to accelerate.

Design-focused approach addresses persistent adoption barriers in diabetes technology

• Despite significant technological advances, adoption rates of advanced insulin delivery systems remain low due to barriers including access and education3.
• ViCentra’s emphasis on making their device “feel more like personal technology than a traditional medical device” with ten color options directly addresses user acceptance challenges that have historically limited adoption.
• The company’s approach recognizes that continuous subcutaneous insulin infusion, while more physiological than traditional methods, has faced adoption challenges due to higher costs and complexity since its introduction in 19792.
• By focusing on user experience and design aesthetics alongside clinical performance, ViCentra is attempting to overcome the barriers that have prevented many patients from transitioning to pump therapy.